These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
163 related articles for article (PubMed ID: 7756658)
1. Percentage of Philadelphia chromosome (Ph)-negative and Ph-positive cells found after autologous transplantation for chronic myelogenous leukemia depends on percentage of diploid cells induced by conventional-dose chemotherapy before collection of autologous cells. Talpaz M; Kantarjian H; Liang J; Calvert L; Hamer J; Tibbits P; Durett A; Claxton D; Giralt S; Khouri I Blood; 1995 Jun; 85(11):3257-63. PubMed ID: 7756658 [TBL] [Abstract][Full Text] [Related]
2. High-dose chemo-radiotherapy followed by autologous Philadelphia chromosome-negative blood progenitor cell transplantation in patients with chronic myelogenous leukemia. Carella AM; Chimirri F; Podestà M; Pitto A; Piaggio G; Dejana A; Lerma E; Pollicardo N; Vassallo F; Soracco M; Benvenuto F; Valbonesi M; Carlier P; Vimercati R; Prencipe E; Gatti AM; Ferrara RA; Incagliato M; Florio G; Frassoni F Bone Marrow Transplant; 1996 Feb; 17(2):201-5. PubMed ID: 8640167 [TBL] [Abstract][Full Text] [Related]
3. Intensive combination chemotherapy and autologous bone marrow transplantation leads to the reappearance of Philadelphia chromosome-negative cells in chronic myelogenous leukemia. Kantarjian HM; Talpaz M; LeMaistre CF; Spinolo J; Spitzer G; Yau J; Dicke K; Jagannath S; Deisseroth AB Cancer; 1991 Jun; 67(12):2959-65. PubMed ID: 1675151 [TBL] [Abstract][Full Text] [Related]
5. Collection of peripheral-blood diploid cells from chronic myelogenous leukemia patients early in the recovery phase from myelosuppression induced by intensive-dose chemotherapy. Kantarjian HM; Talpaz M; Hester J; Feldman E; Korbling M; Liang J; Rios MB; Smith TL; Calvert L; Deisseroth AB J Clin Oncol; 1995 Mar; 13(3):553-9. PubMed ID: 7884415 [TBL] [Abstract][Full Text] [Related]
6. High doses of cyclophosphamide, etoposide and total body irradiation followed by autologous stem cell transplantation in the management of patients with chronic myelogenous leukemia. Kantarjian HM; Talpaz M; Andersson B; Khouri I; Giralt S; Rios MB; Champlin R; Hester J; Deisseroth AB Bone Marrow Transplant; 1994 Jul; 14(1):57-61. PubMed ID: 7951120 [TBL] [Abstract][Full Text] [Related]
7. Leukemic burden in subpopulations of CD34+ cells isolated from the mobilized peripheral blood of alpha-interferon-resistant or -intolerant patients with chronic myeloid leukemia. Van den Berg D; Wessman M; Murray L; Tong J; Chen B; Chen S; Simonetti D; King J; Yamasaki G; DiGiusto R; Gearing D; Reading C Blood; 1996 May; 87(10):4348-57. PubMed ID: 8639795 [TBL] [Abstract][Full Text] [Related]
8. Collection of 'normal' blood repopulating cells during early hemopoietic recovery after intensive conventional chemotherapy in chronic myelogenous leukemia. Carella AM; Podesta M; Frassoni F; Raffo MR; Pollicardo N; Pungolino E; Vimercati R; Sessarego M; Parodi C; Rabitti C Bone Marrow Transplant; 1993 Sep; 12(3):267-71. PubMed ID: 7694724 [TBL] [Abstract][Full Text] [Related]
9. Therapy of acute phase chronic myelogenous leukemia with intensive chemotherapy, blood cell autotransplant and cyclosporine A. Carella AM; Gaozza E; Raffo MR; Carlier P; Frassoni F; Valbonesi M; Lercari G; Sessarego M; Defferrari R; Guerrasio A Leukemia; 1991 Jun; 5(6):517-21. PubMed ID: 1676080 [TBL] [Abstract][Full Text] [Related]
10. Use of granulocyte-macrophage colony-stimulating factor (GM-CSF) in combination with hydroxyurea as post-transplant therapy in chronic myelogenous leukemia patients autografted with unmanipulated hematopoietic cells. Carlo-Stella C; Regazzi E; Andrizzi C; Savoldo B; Garau D; Montefusco E; Vignetti M; Mandelli F; Rizzoli V; Meloni G Haematologica; 1997; 82(3):291-6. PubMed ID: 9234574 [TBL] [Abstract][Full Text] [Related]
11. Idarubicin, intermediate-dose cytarabine, etoposide, and granulocyte-colony-stimulating factor are able to recruit CD34+/HLA-DR- cells during early hematopoietic recovery in accelerated and chronic phases of chronic myeloid leukemia. Carella AM; Frassoni F; Podestá M; Pungolino E; Pollicardo N; Ferrero R; Soracco M J Hematother; 1994; 3(3):199-202. PubMed ID: 7530135 [TBL] [Abstract][Full Text] [Related]
12. Autologous transplantation with Philadelphia-negative progenitor cells for patients with chronic myeloid leukaemia (CML) failing to attain a cytogenetic response to alpha interferon. McBride NC; Cavenagh JD; Newland AC; Lillington DM; Murrell C; Kelsey SM Bone Marrow Transplant; 2000 Dec; 26(11):1165-72. PubMed ID: 11149726 [TBL] [Abstract][Full Text] [Related]
13. Successful treatment of lymphoid blastic crisis in chronic myelogenous leukemia with the additional bcr/abl transcript using imatinib-combined chemotherapy and high-dose chemotherapy with allogeneic bone marrow stem cell transplantation. Kawano N; Okuda S; Yoshida S; Kugimiya H; Ito M; Horikawa N; Chosa N; Hisakata T; Fukudome T; Sakurai R; Yamashita K; Ueda A; Kanda Y Int J Hematol; 2011 Dec; 94(6):561-6. PubMed ID: 22057509 [TBL] [Abstract][Full Text] [Related]
14. Selective overshoot of Ph-negative blood hemopoietic cells after intensive idarubicin-containing regimen and their repopulating capacity after reinfusion. Carella AM; Podestà M; Frassoni F; Pungolino E; Pollicardo N; Raffo MR; Ferrero R; Benvenuto F; Figari O; Giordano D Stem Cells; 1993 Oct; 11 Suppl 3():67-72. PubMed ID: 7905325 [TBL] [Abstract][Full Text] [Related]
15. Less intense conditioning with fludarabine, cyclophosphamide, idarubicin and etoposide (FCIE) followed by allogeneic unselected peripheral blood stem cell transplantation in elderly patients with leukemia. Schlenk RF; Hartmann F; Hensel M; Jung W; Weber-Nordt R; Gabler A; Haas R; Ho AD; Trümper L; Döhner H Leukemia; 2002 Apr; 16(4):581-6. PubMed ID: 11960336 [TBL] [Abstract][Full Text] [Related]
17. BCR/ABL-negative primitive progenitors suitable for transplantation can be selected from the marrow of most early-chronic phase but not accelerated-phase chronic myelogenous leukemia patients. Verfaillie CM; Bhatia R; Miller W; Mortari F; Roy V; Burger S; McCullough J; Stieglbauer K; Dewald G; Heimfeld S; Miller JS; McGlave PB Blood; 1996 Jun; 87(11):4770-9. PubMed ID: 8639848 [TBL] [Abstract][Full Text] [Related]
18. Philadelphia chromosome-negative engraftment after autologous transplantation with granulocyte-macrophage colony-stimulating factor for chronic myeloid leukemia. Gladstone DE; Bedi A; Miller CB; Noga SJ; Griffin CA; Piantadosi S; Cagnoni PJ; Brodsky RA; Smith BD; Douglas TT; Shpall EJ; Jones RJ Biol Blood Marrow Transplant; 1999; 5(6):394-9. PubMed ID: 10595817 [TBL] [Abstract][Full Text] [Related]
19. Comparative analysis of autografting in chronic myelogenous leukemia: effects of priming regimen and marrow or blood origin of stem cells. Verfaillie CM; Bhatia R; Steinbuch M; DeFor T; Hirsch B; Miller JS; Weisdorf D; McGlave PB Blood; 1998 Sep; 92(5):1820-31. PubMed ID: 9716614 [TBL] [Abstract][Full Text] [Related]
20. [Prognosis of children with chronic myeloid leukemia: a retrospective analysis of 75 patients]. Creutzig U; Ritter J; Zimmermann M; Klingebiel T Klin Padiatr; 1996; 208(4):236-41. PubMed ID: 8926689 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]